Nevertheless, our findings show that PI3K p110γ inhibition may serve as a strategy for potentially enhancing the cytotoxic response against poorly immunogenic HNSCC and likely potentiates HNSCC treatment when used in combination with selective checkpoint inhibitors. The gene discussed is PIK3CG; the disease is head and neck squamous cell carcinoma.